VivoSeq
Oncology

Head Neck Cancer

4

Pipeline Programs↗

11

Active Trials↗

8

Companies Involved↗

Head Neck Cancer is an early-stage landscape with 4 programs across 8 companies. The most active players are Merck & Co., Avyxa, Teva.

Intelligence

Pipeline Metrics

Competitive Density

35/100

Pipeline Velocity

19/100

Mech. Concentration

50/100

Completion Rate

86/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 2A

Avyxa

1 program

Phase 2Teva logo

Teva

1 program

Phase 2O

OncoZenge AB

2 programs

Phase 3S

Second Life Therapeutics

1 program

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

SL-28.

Second Life Therapeutics

Phase 1
No programs
Phase 23

Pembrolizumab

Merck & Co.

Carboplatin

Avyxa

Paclitaxel

Teva

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 67% of 6 pipeline programs.

Analysis

Trial Status

27

clinical trials

Completed12 · 44%
Recruiting5 · 19%
Active, not recruiting4 · 15%
Unknown status2 · 7%
Terminated2 · 7%
Not yet recruiting2 · 7%

Clinical Trials

Trial Activity

27 trials

Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05595590·20 enrolled
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
Recruiting·UUniversity of Alabama at Birmingham·Phase 2·NCT04511078·25 enrolled
Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
Recruiting·UUNICANCER·Phase 3·NCT04747054·102 enrolled
A Randomized, Open-label, Phase III Trial to Assess the Efficacy and Safety of BupiZenge Compared to Lidocaine for Pain Associated With Oral Mucositis in Head and Neck Cancer
Recruiting·OOncoZenge AB·Phase 3·NCT07672236·150 enrolled
A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours
Recruiting·SSecond Life Therapeutics·Preclinical·NCT07341737·60 enrolled
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)
Active, not recruiting·PProvidence Health & Services·Phase 2·NCT04938609·28 enrolled
"QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer
Active, not recruiting·UUniversity of Oklahoma·Phase 2·NCT04373642·30 enrolled
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer
Active, not recruiting·PProvidence Health & Services·Phase 1/2·NCT03247712·22 enrolled
Phase II Study of First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
Active, not recruiting·WWake Forest University Health Sciences·Phase 2·NCT04858269·31 enrolled
Safety, Tolerability, PK, and Efficacy of CD-001 in Advanced Head & Neck Cancers
Not yet recruiting·WWest China Hospital·Phase 1·NCT07072325·9 enrolled
Randomized Multicenter Clinical Trial of Early Integration of Palliative Care With Chemoradiotherapy Versus Chemoradiotherapy Alone in Patients With Locally Advanced Unresectable Head and Neck Cancer.
Not yet recruiting·PPortuguese Oncology Institute, Coimbra·Preclinical·NCT07671573·64 enrolled
Treatment of Head & Neck Cancer With Chemotherapy and Radiation
Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00392704·60 enrolled
BIBW 2992 (Afatinib) in Head & Neck Cancer
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT00514943·124 enrolled
CIML NK Cell in Head & Neck Cancer
Completed·—·Phase 1·NCT04290546·11 enrolled
Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy
Completed·AAssistance Publique Hopitaux De Marseille·Phase 4·NCT02484677·12 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)